Trial Profile
Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2022
Price :
$35
*
At a glance
- Drugs Pegapamodutide (Primary) ; Exenatide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors OPKO Health
- 19 Mar 2021 Metformin added in arms and interventions.
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 30 Jun 2016 Results published in a joint media release by OPKO Health and Transition Therapeutics.